Results 81 to 90 of about 45,526 (248)
Клиническая онкогематология, 2016 Background & Aims. The chimeric tyrosine kinase Bcr-Abl triggers malignant transformation of myeloid cells via phosphorylation of a number of substrates including the CrkL adaptor protein.
E. S. Kolotova +9 more
doaj +1 more source
Long Non-Coding RNAs: New Players in Hematopoiesis and Leukemia [PDF]
, 2015 Long non-coding RNAs (lncRNAs) are important regulators of gene expression that influence almost every step in the life cycle of genes, from transcription to mRNA splicing, RNA decay, and translation.
Ballarino, Monica +2 more
core +2 more sources
Oncogenic fusion protein BCR-FGFR1 requires the breakpoint cluster region-mediated oligomerization and chaperonin Hsp90 for activation. [PDF]
, 2020 Mutation and translocation of fibroblast growth factor receptors often lead to aberrant signaling and cancer. This work focuses on the t(8;22)(p11;q11) chromosomal translocation which creates the breakpoint cluster region (BCR) fibroblast growth factor ...
Bisom-Rapp, Ezra W +4 more
core +2 more sources
Cancer Science, EarlyView.Mass spectrometry‐based phosphoproteomics for mechanistic dissection of cancer signaling pathways and uncovering therapeutic vulnerabilities. ABSTRACT Protein phosphorylation is a central post‐translational modification regulating cellular signaling, frequently dysregulated in cancer.
Hirokazu Shoji +2 more
wiley +1 more source
eLifePhiladelphia chromosome-positive (Ph+) leukemia is a fatal hematological malignancy. Although standard treatments with tyrosine kinase inhibitors (TKIs) have achieved remarkable success in prolonging patient survival, intolerance, relapse, and TKI ...
Mengya Zhao +10 more
doaj +1 more source
BMC Cancer, 2012 Background Philadelphia positive leukemias are characterized by the presence of Bcr-Abl fusion protein which exhibits an abnormal kinase activity. Selective Abl kinase inhibitors have been successfully established for the treatment of Ph (+) leukemias ...
Khateb Mamduh +7 more
doaj +1 more source
Development of resistance to dasatinib in Bcr/Abl-positive acute lymphoblastic leukemia [PDF]
Leukemia, 2010 Dasatinib is a potent dual Abl/Src inhibitor approved for treatment of Philadelphia chromosome-positive (Ph-positive) leukemias. At a once-daily dose and a relatively short half-life of 3-5 h, tyrosine kinase inhibition is not sustained. However, transient inhibition of K562 leukemia cells with a high-dose pulse of dasatinib or long-term treatment with
Fei, F +5 more
openaire +4 more sources
Targeting HSPA8 to repress GPX4 and induce ferroptosis in BCR-ABL positive leukemia
Biomedical TechnologyBCR-ABL positive (BCR-ABL+) leukemia is driven by constitutive activation of tyrosine kinase activity, with tyrosine kinase inhibitors (TKIs) serving as the standard treatment. However, resistance to TKIs remains a significant clinical challenge. In this
Shuxin Zhong +12 more
doaj +1 more source
Targeting self-renewal pathways in myeloid malignancies [PDF]
, 2013 A fundamental property of hematopoietic stem cells (HSCs) is the ability to self-renew. This is a complex process involving multiple signal transduction cascades which control the fine balance between self-renewal and differentiation through ...
Copland, M., Sands, W.A., Wheadon, H.
core +2 more sources
USP10 in Neurological Disorders: Mechanistic Insights and Emerging Therapeutic Strategies
Annals of the New York Academy of Sciences, EarlyView.USP10 is a deubiquitinating enzyme that affects neurological diseases through multiple mechanisms, including the accumulation of toxic proteins, autophagy, and immune responses. In this review, we discuss the structure and characteristics of USP10 and summarize the role of USP10 in neurological disorders.
Celemuge +5 more
wiley +1 more source